Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the 311 Institute, a global futures think tank working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future.” Regularly featured in the global media, including AP, BBC, CNBC, Discovery, RT, and Viacom, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring several Education and Lunar XPrize teams, building the first generation of biological computers and re-envisioning global education with the G20, and helping the world’s largest conglomerates ideate the next 20 years of intelligent devices and machines. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Bain & Co, BCG, BOA, Blackrock, Bentley, Credit Suisse, Dell EMC, Dentons, Deloitte, Du Pont, E&Y, HPE, Huawei, JPMorgan Chase, KPMG, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, UBS, and many more.
WHY THIS MATTERS IN BRIEF
About 1 in 100 people have Celiac disease, and this could be the cure they’re all waiting for.
Recently there have been several interesting vaccine breakthroughs, including the development of Contagious Vaccines, that mean vaccinate one person and suddenly everyone has the immunity, and Cancer vaccines which, as they say, kill Cancer, but now an experimental “vaccine” for Celiac disease is set to be tested in a new clinical trial to see if the treatment can protect patients with the condition from the effects of eating gluten, or, in other words, allow those patients to eat gluten safely. The treatment, called Nexvax2 and made by the biotech company ImmusanT, is a type of immunotherapy that aims to “reprogram the immune system to be tolerant of gluten,” the researchers said.
Celiac disease is a condition in which people’s immune systems react abnormally to gluten, a protein found in wheat, rye and barley, and this reaction damages the lining of the small intestine. The condition affects about 1 out of every 100 people in the US.
Currently, the only way to manage celiac disease is for patients to avoid foods containing gluten for the rest of their lives, but even with the rise in popularity of gluten-free foods, such diets can still be difficult to follow, and patients may be inadvertently exposed to the protein.
“Even the most diligent patients can suffer the adverse effects of accidental exposure,” says study researcher Jason Tye-Din, head of celiac research at the Walter and Eliza Hall Institute of Medical Research in Australia.
Nexvax2 works in a way that’s similar to allergy shots. The treatment, which consists of twice weekly injections administered over a 16 week period, is made up of molecules called peptides, which elicit an immune response in patients with celiac disease. In theory, exposure to the peptides over time could help reprogram immune cells called T cells to become tolerant of gluten and no longer trigger an immune response to the substance, according to ImmusanT. This could allow patients with celiac disease to eat a diet that includes gluten.
The vaccine is intended for patients with celiac disease who carry an immune system gene called HLA-DQ2.5 that is found in about 90 percent of individuals with the condition, the company said.
In an earlier trial of Nexvax2 in a small group of people, researchers showed that the vaccine was safe and well-tolerated among patients with celiac disease. The new study, which will include around 150 patients, aims to further test the safety, as well as the effectiveness of the treatment.
“This [new] trial is important in establishing clinical proof of concept for a treatment that would provide benefit beyond that of the gluten-free diet,” said Tye-Din.
The company is currently recruiting patients in Australia, New Zealand and the US to participate in the trial, according to ClinicalTrials.gov.